Sandbox Reserved 971
From Proteopedia
(New page: {{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Caption ...) |
|||
Line 18: | Line 18: | ||
== References == | == References == | ||
<references/> | <references/> | ||
+ | ==ST2/IL33 complex== | ||
+ | <StructureSection load='4kc3' size='340' side='right' caption='Caption for this structure' scene=''> | ||
+ | |||
+ | == Introduction == | ||
+ | |||
+ | Interleukin 33 is a cytokine member of the IL-1 superfamily. Cytokines are proteins involved in cell signaling. Their role is to regulate the function and the activity of other cells. IL-33 is involved in innate and adaptive immune responses. | ||
+ | |||
+ | In 2005, IL-33 was identified as a ligand for the transmembrane receptor ST2 and it IL-1 receptor accessory protein (IL-1RAcP), both members of the interleukin-1 receptor family. IL-33/ST2 signaling is involved in T-cell immune responses. | ||
+ | |||
+ | We will focuse on the interaction bewteen IL33 and the ST2 ectodomain (as you can see <scene name='61/614056/Name_il33_st2/1'>here</scene>). | ||
+ | |||
+ | |||
+ | |||
+ | == Function == | ||
+ | |||
+ | '''Caracteristics of IL-33:''' | ||
+ | |||
+ | IL-33 is constitutively expressed in several cells, such as epithelial or endothelial cells. IL-33 is also expressed in an inducible way by immune cells. In this case, the constitutive expression of IL-33 is very low or absent. In mast cells, the expression of IL-33 is induced by the calcium, but the mechanisms are still unclear. IL-33 is secreted in damaged tissues, where it activates the immune response. | ||
+ | |||
+ | '''Target cells:''' | ||
+ | |||
+ | ST2 exists in a soluble form (sST2) and a transmembrane form (ST2L). The both forms can interact with IL-33. ST2L are expressed in T lymphocytes, when they are specializing into Th2 cells (T helper type 2 cells, a specific type of T lymphocytes). This specialization occurs in the presence of IL4, expected to be secreted by polynuclear basophils. | ||
+ | |||
+ | IL-33 interacts with the ectodomain of ST2L. This interaction provokes the recruitment of the myeloid differentiation primary-response protein 88 (MYD88) complex, which is involved in the immune response against commune viral infections and some bacterial infections. | ||
+ | When IL-33 interacts with the sST2, it inhibits the fixation of IL-33 of the ectodomain of ST2. | ||
+ | |||
+ | |||
+ | |||
+ | == Structure == | ||
+ | |||
+ | '''Overall structure:''' | ||
+ | |||
+ | The understanding of the interaction of IL-33 with its receptors has been discovered thanks to the determination of the crystal structure of IL-33 in complex with ectodomain of ST2. | ||
+ | |||
+ | Besides, the combination of crystallography and small-angle X-ray-scattering methods reveal that ST2 has a very flexible conformation, contrary to IL-1RAcP. In fact, ST2 is constituted of three IgG-like domains (<scene name='61/614056/Domains_d1d2d3_de_st2/1'>D1 to D3</scene>). D1 and D2 gather to form a single D1D2 module, connected through a linker with the D3 domain. ST2 contains also <scenename='61/614056/Three_residues_of_st2_with_nag/3'>three residues</scene> linked with NAG and an <scene name='61/614056/St2_hydrophobic_patch/1'>hydrophobic patch</scene> which is involved in the interaction with the other receptor, IL-1RAcP. | ||
+ | |||
+ | This conformational specificity provides a capactity of ligand-binding with IL-33. Moreover, the rigidity of IL-1RAcP explains that it can not bind the IL-33 ligand directly. | ||
+ | |||
+ | In humans, IL-33 in its full length is composed of 270 residues and is biologically active. | ||
+ | The model includes IL-33 residues Ser117 to Ser268 and ST2 residues Ser21 to Arg317. | ||
+ | |||
+ | The structure of IL-33 consists in a <scene name='61/614056/Beta_sheet_of_il33/2'>12 β-strands</scene> forming a β-trefoil structure. It also contains an <scene name='61/614056/Il33_alpha_helix/1'>alpha helix</scene>. Specific loops, such as the β4-β5 loop, are involved in the interaction with the accessory receptor IL-1RAcP when IL-33 is bound to ST2. | ||
+ | |||
+ | '''IL-33/ST2 interactions:''' | ||
+ | |||
+ | In the complex, IL-33 interacts with the three domains of ST2. The binding interface is very large and composed of two separate sites. | ||
+ | |||
+ | In the <scene name='61/614056/Interaction_site_1/5'>first binding site</scene>, thirteen IL-33 residues from β-loops are in contact with the D1D2 module of ST2: the four marked acids residues of IL-33 form a salt-bridge with five marked ST2 residues respectively. Besides, Glu144 and Asp149 form hydrogen bonds with main-chain atoms of ST2. IL-33 mutation of one of the acid residues (144, 148, 149 and 244) highly decreases the affinity of ST2 for IL-33. | ||
+ | |||
+ | In the <scene name='61/614056/Interaction_site_2/2'>second binding site</scene>, eight IL-33 residues from β-strands interact with the D3 domain of ST2. | ||
+ | |||
+ | There are both hydrophobic and hydrophilic interactions. Residues of IL-33 form an hydrophobic cluster (IL-33 residues Tyr163 and Leu182 and ST2 residues Leu246, Leu306, and Leu311). A salt-bridge interaction occurs between acidic residue Glu165 and Arg313 of ST2. | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | </StructureSection> | ||
+ | == References == | ||
+ | 1. Xi Liua, Michal Hammelb, Yanfeng Hea, John A. Tainerc,d, U-Ser Jenge, Linqi Zhangf, Shuying Wangg, and Xinquan Wanga ''Structural insights into the interaction of IL-33 with its receptors'' (2013) | ||
+ | [http://www.pnas.org/content/110/37/14918.full DOI: 10.1073/pnas.1308651110] | ||
+ | |||
+ | 2. Ananda S. Mirchandani, Robert J. Salmond, Foo Y. ''Interleukin-33 and the function of innate lymphoid cells'' (2012) [http://dx.doi.org/10.1016/j.it.2012.04.005 DOI: 10.1016/j.it.2012.04.005] | ||
+ | |||
+ | 3. Rahul Kakkar & Richard T. Lee. ''The IL-33/ST2 pathway: therapeutic target and novel biomarker'' (2008) [http://www.nature.com/nrd/journal/v7/n10/abs/nrd2660.html DOI: 10.1038/nrd2660] | ||
+ | |||
+ | 4. Lécart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, Boulay V, Pène J, Kuroiwa K, Tominaga S, Yssel H. ''Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface.'' http://www.ncbi.nlm.nih.gov/pubmed/12355452 | ||
+ | |||
+ | 5. Chia-Lin Hsu and Paul J Bryce. ''Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway.'' http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541686/ | ||
+ | |||
+ | |||
+ | |||
+ | [[Category: Homo sapiens]] | ||
+ | [[Category: Liu, X.]] | ||
+ | [[Category: Wang, X Q.]] | ||
+ | [[Category: Beta-trefoil]] | ||
+ | [[Category: Ig-like domain]] | ||
+ | [[Category: Immune system]] |
Revision as of 17:04, 8 January 2015
This Sandbox is Reserved from 15/11/2014, through 15/05/2015 for use in the course "Biomolecule" taught by Bruno Kieffer at the Strasbourg University. This reservation includes Sandbox Reserved 951 through Sandbox Reserved 975. |
To get started:
More help: Help:Editing |
Contents |
Your Heading Here (maybe something like 'Structure')
|
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
ST2/IL33 complex
|
References
1. Xi Liua, Michal Hammelb, Yanfeng Hea, John A. Tainerc,d, U-Ser Jenge, Linqi Zhangf, Shuying Wangg, and Xinquan Wanga Structural insights into the interaction of IL-33 with its receptors (2013) DOI: 10.1073/pnas.1308651110
2. Ananda S. Mirchandani, Robert J. Salmond, Foo Y. Interleukin-33 and the function of innate lymphoid cells (2012) DOI: 10.1016/j.it.2012.04.005
3. Rahul Kakkar & Richard T. Lee. The IL-33/ST2 pathway: therapeutic target and novel biomarker (2008) DOI: 10.1038/nrd2660
4. Lécart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, Boulay V, Pène J, Kuroiwa K, Tominaga S, Yssel H. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. http://www.ncbi.nlm.nih.gov/pubmed/12355452
5. Chia-Lin Hsu and Paul J Bryce. Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541686/